India’s CDMO Sector Poised for Global Shift as Pharma Diversifies from China
The global pharmaceutical supply chain is undergoing a structural realignment as multinational companies seek to reduce their reliance on Chinese manufacturing. Indian Contract Development and Manufacturing Organisations (CDMOs) are emerging as the primary beneficiaries of this shift, positioning themselves as trusted, high-quality alternatives for global drugmakers.
India Emerges as the Preferred Alternative to China
The transition away from Chinese manufacturing hubs is no longer a theoretical possibility but an active trend. According to Sivaramakrishnan Chittor, CFO of Sai Life Sciences, the movement began nearly two years ago, long before recent regulatory scrutiny intensified around Chinese giants like WuXi AppTec.
The inclusion of certain entities in regulatory lists has provided much-needed clarity for global pharmaceutical firms to diversify their supply chains. Indian CDMOs are capitalizing on this by scaling up operations and increasing capital expenditure (capex) to meet rising demand. Sai Life Sciences, which works with 19 of the top 25 global pharmaceutical companies, is at the forefront of this transition.
Strategic Capex and Financial Resilience
To meet the growing global demand, Sai Life Sciences has announced a massive capacity expansion plan. The company intends to invest between ₹1,100 crore and ₹1,300 crore by FY27. This expansion will be funded through a combination of internal accruals and debt, a move made possible by the company's healthy balance sheet, which currently carries minimal to no debt.
While new production facilities are expected to come online by the end of the current financial year, management noted that it may take a couple of years to reach optimal capacity utilization. Despite these long-term investments, the company has maintained its revenue growth guidance of a 15-20% CAGR.
Shifting Revenue Mix and Commercial Growth
A significant indicator of India's rising importance is the changing revenue composition of major players. Over the last four years, Sai Life Sciences has seen the contribution from large global pharmaceutical companies rise from 28% to 49%. This highlights a deeper integration of Indian manufacturers into the core business models of "Big Pharma."
Furthermore, the nature of the work being done in India is evolving. Historically, Indian firms were often used for clinical supplies; however, there is a notable shift toward commercial-scale manufacturing. Sai Life Sciences reported that its number of Phase III and pre-registration molecules has nearly doubled, growing from six to eleven molecules. This reflects growing global confidence in India’s ability to handle complex, late-stage development and large-scale commercial production.
A Gradual but Permanent Transformation
While the opportunity is immense, experts caution that the shift will not happen overnight. Because pharmaceutical manufacturing is a highly regulated sector, moving a product from one manufacturer to another requires rigorous regulatory approvals and long product transfer timelines. Consequently, the full impact of this supply chain realignment may only become visible in the coming years rather than in immediate quarterly results.
Key Takeaways
- Supply Chain Diversification: Global pharma companies are actively moving manufacturing footprints away from China toward India to mitigate regulatory and supply chain risks.
- Increased Commercial Confidence: Indian CDMOs are moving beyond clinical trial supplies to handling high-value Phase III and commercial-scale manufacturing projects.
- Aggressive Capacity Expansion: Major Indian players like Sai Life Sciences are investing up to ₹1,300 crore in capacity to capture the long-term structural growth in the sector.